Sufficient information on WORLD HEALTH ORGANISATION, a medico 3rd year MBBS should know.
This PPT is made by using various textbooks and reference books like- K. Park, etc.
For any issue or query, please write to me dr.kaushik.apaar@gmail.com.
WHO is working to ensure that everyone has access to quality health care.
In many countries, there is little money available to spend on health. This
results in inadequate hospitals and clinics, a short supply of essential
medicines and equipment, and a critical shortage of health workers.
Worse, in some parts of the world, large numbers of health workers are
dying from the very diseases which they are trying to prevent and treat.
WHO works with countries to help them plan, educate and manage the
health workforce, for example, by advising on policies to recruit and retain
people working in health.
WHO is working to ensure that everyone has access to quality health care.
In many countries, there is little money available to spend on health. This
results in inadequate hospitals and clinics, a short supply of essential
medicines and equipment, and a critical shortage of health workers.
Worse, in some parts of the world, large numbers of health workers are
dying from the very diseases which they are trying to prevent and treat.
WHO works with countries to help them plan, educate and manage the
health workforce, for example, by advising on policies to recruit and retain
people working in health.
In detail about international health agencies ,
*definition of international health
Background for establishing international health community
*previous int. Health organisation and there basis of establishment
* birth of who
*who
*unicef
*other UN agencies : UNDP ,UNFPA ,FAO,ILO
*international red cross
* other private ngos
A presentation on WHO containing-
Introduction
Brief history of WHO
Formation of WHO
Functions of WHO
Governance of WHO
Brief notes on DG of WHO
Regions of WHO
WHO regional office
Regional Directors of WHO
SEARO
Brief notes on Regional Director of SEARO
World Health Organization 2008 - Primary Health Care: Now More Than EverNick Jacobs
Why a renewal of primary health care (PHC), and why now, more than ever? Globalization is putting the social cohesion of many countries under stress, and health systems are clearly not performing as well as they could and should. People are increasingly impatient with the inability of health services to deliver. Few would disagree that health systems need to respond better – and faster – to the challenges of a rapidly changing world.
Global health is the health of populations in the global context; it has been defined as "the area of study, research and practice that places a priority on improving health and achieving equity in health for all people worldwide".Problems that transcend national borders or have a global political and economic impact are often emphasized.Thus, global health is about worldwide health improvement (including mental health), reduction of disparities, and protection against global threats that disregard national borders.Global health is not to be confused with international health, which is defined as the branch of public health focusing on developing nations and foreign aid efforts by industrialized countries.Global health can be measured as a function of various global diseases and their prevalence in the world and threat to decrease life in the present day.
In detail about international health agencies ,
*definition of international health
Background for establishing international health community
*previous int. Health organisation and there basis of establishment
* birth of who
*who
*unicef
*other UN agencies : UNDP ,UNFPA ,FAO,ILO
*international red cross
* other private ngos
A presentation on WHO containing-
Introduction
Brief history of WHO
Formation of WHO
Functions of WHO
Governance of WHO
Brief notes on DG of WHO
Regions of WHO
WHO regional office
Regional Directors of WHO
SEARO
Brief notes on Regional Director of SEARO
World Health Organization 2008 - Primary Health Care: Now More Than EverNick Jacobs
Why a renewal of primary health care (PHC), and why now, more than ever? Globalization is putting the social cohesion of many countries under stress, and health systems are clearly not performing as well as they could and should. People are increasingly impatient with the inability of health services to deliver. Few would disagree that health systems need to respond better – and faster – to the challenges of a rapidly changing world.
Global health is the health of populations in the global context; it has been defined as "the area of study, research and practice that places a priority on improving health and achieving equity in health for all people worldwide".Problems that transcend national borders or have a global political and economic impact are often emphasized.Thus, global health is about worldwide health improvement (including mental health), reduction of disparities, and protection against global threats that disregard national borders.Global health is not to be confused with international health, which is defined as the branch of public health focusing on developing nations and foreign aid efforts by industrialized countries.Global health can be measured as a function of various global diseases and their prevalence in the world and threat to decrease life in the present day.
International health, also called geographic medicine, international medicine, or global health, is a field of health care, usually with a public health emphasis, dealing with health across regional or national boundaries.
The emergence of the concept of "International Health." Traces back to the pre/post world war period and how it impacted the formation of various international health organization for various strata of the society.
WHO, the United Nations specialized agency for health, was established on 7th April
1948.
WHO’s objective, is the attainment by all peoples of the highest possible level of health.
Health is defined in WHO’s constitution as a state of complete physical, mental and
social well-being and not merely the absence of disease or infirmity.
It is governed by 192 member states through the World Health Assembly(WHA).
The main tasks of WHA are to approve the ‘WHO’ programme and the budget for the
same and to decide major policy questions.
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
2. TIME LINE
1945
• An international conference at San Francisco held to set up united nations.
• China and Brazil proposed to form an international health organisation.
1946
• An international conference at New York held to set up.
• At that conference, Interim Commission was formed to prepare the ground for the new organisation.
1948
• On 7th April, 1948, WHO was established as an international health organisation.
3. WHO- AN ORGANISATION
• Who as an organisation, is non-political, specialised health agency of the united nations.
• The constitution of who WAS framed by “Technical Preparatory Committee” in 1946
under the leadership of Rene Sand. The constitution was approved by the international
conference at New York in the same year constituting about 51 countries.
• The constitution was came into force on 7th April, 1948. This day is thus celebrated as
World Health Day.
• Headquarters- Geneva, Switzerland.
4. OBJECTIVES OF WHO
• WHO has its own constitution, own governing bodies, own membership and own
budget.
• Some key objectives as mentioned in constitution are as follows:-
Health is a state of complete physical, mental and social well being and not merely an absence
of disease.
Health is one of the fundamental rights of every human being without distinction of race,
religion, political belief, economic condition and social condition.
Unequal development in different countries in promotion of health and control of disease, is a
danger.
Governments are responsible for providing health to their citizens.
5. MEMBERSHIP AT WHO
• Membership is open to all countries.
• Any country can become a member of WHO.
• Each and every member has to contribute yearly to the budget for WHO. all contributors will
get the services and aids provided by the organisation.
• In 1948, WHO has only 56 members.
• Now WHO has around 194 members and 2 associative members.
• Associative member: Territories which are not responsible for the conduct of their
international relations are classified as associative members.
6. WORKS OF WHO
• As per constitution- ‘to act as the directive and coordinative authority on all international health work’.
This function allows WHO:
1. To identify collectively priority health programs throughout the world.
2. To define collectively health policies and targets to cope with them.
3. To devise collectively strategies, principles and programmes to attain the targets.
• Prevention and control of specific diseases
• Development of comprehensive health programmes.
• Biomedical research.
• Family health.
• Environmental health
• Health statistics
• Health literature amd information
• Cooperation with other organisations
7. STRUCTURE OF WHO
• WHO has 3 principal organs:
1. The World Health Assembly
2. The Executive Board
3. The Secretariat
8. 1. THE WORLD HEALTH ASSEMBLY
• Health parliament of the nations.
• It meets annually mostly at Headquarters, Geneva usually in the month of May.
• All members of the organisation send their representatives and each one has 1 vote.
• Functions:
1. To determine international health policies and programmes
2. To review the work of past year
3. To approve the budget needed for the following year
4. To elect a person to serve for 3 years on the executive board and to replace the retiring
members
9. 2. THE EXECUTIVE BOARD
• Total members- 34.
• It meets atleast twice a year usually in January and shortly after the WHA in May.
• Functions:
1. To give effect to the policies and decisions of the assembly.
2. To act immediately in times of emergency like epidemics/tsunamis/earthquake/flood, etc as
and when the action is needed.
10. 3. THE SECRETARIAT
• Head- Director General. Usually assisted by Asstt. Director Generals.
• Its main function is to provide member states with technical and managerial support for
their national health programs.